GMO's Tom Hancock on Buying Quality Tech Stocks and UnitedHealth Amidst AI Developments

Buying Quality Tech Stocks

• 💡 GMO is still a buyer of large-cap quality tech stocks, despite markets being near all-time highs.
• 🚀 Developments in AI technology and investment from entities like Saudi Arabia are seen as positive long-term indicators.
• 🎯 The focus is on the underlying technology and its potential for long-term profitability, rather than short-term policy or market sentiment.

Market Pivots and AI

• ⚠️ Market behavior during uncertainty often shows risk aversion, particularly towards long-duration assets and unproven profitability.
• 📈 This aversion can create buying opportunities for growth stocks, as seen at the end of 2022 and early 2023.
• ⚡ While a recent buying window may have closed quickly, the underlying dynamics of AI development continue to be a key factor.

UnitedHealth Group (UNH) Investment

• 📌 UnitedHealth Group is considered a buy despite recent stock declines and reported business mistakes.
• 🤝 Board member buying and a heavily stock-loaded compensation package for the new CEO signal strong conviction within the organization.
• 🏥 While UnitedHealth made mistakes in its Medicare Advantage business, the company has the ability to reprice annually and possesses a strong balance sheet and great cash flow to address issues.
• 🔍 Concerns about negative news flow, litigation threats, and Medicare coding practices are addressed by explaining that higher payments for conditions like diabetes reflect higher actuarial liability, similar to life insurance pricing for smokers.
• ✅ The business mistakes are seen as fixable, and the return of Steve Hemsley as CEO is viewed positively.